Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Human Genetic Susceptibility of Leprosy Recurrence.

Uaska Sartori PV, Penna GO, Bührer-Sékula S, Pontes MAA, Gonçalves HS, Cruz R, Virmond MCL, Dias-Baptista IMF, Rosa PS, Penna MLF, Medeiros Fava V, Stefani MMA, Távora Mira M.

Sci Rep. 2020 Jan 28;10(1):1284. doi: 10.1038/s41598-020-58079-3.

2.

Ascaris lumbricoides coinfection reduces tissue damage by decreasing IL-6 levels without altering clinical evolution of pulmonary tuberculosis or Th1/Th2/Th17 cytokine profile.

Santos JHA, Bührer-Sékula S, Melo GC, Cordeiro-Santos M, Pimentel JPD, Gomes-Silva A, Costa AG, Saraceni V, Da-Cruz AM, Lacerda MVG.

Rev Soc Bras Med Trop. 2019 Dec 2;52:e20190315. doi: 10.1590/0037-8682-0315-2019. eCollection 2019.

3.

Reply of the authors of the Continuing Medical Education article to Dr. Jaison Barreto and Dr. Laila Laguiche.

Cruz RC, Bührer-Sékula S, Penna MLF, Penna GO, Talhari S.

An Bras Dermatol. 2018 Jul-Aug;93(4):625-626. doi: 10.1590/abd1806-4841.201893404. No abstract available.

4.

Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.

Cruz RCDS, Bührer-Sékula S, Penna GO, Moraes MEA, Gonçalves HS, Stefani MMA, Penna MLF, Pontes MAA, Talhari S.

An Bras Dermatol. 2018 Jun;93(3):377-384. doi: 10.1590/abd1806-4841.20186709.

5.

Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT.

Hungria EM, Bührer-Sékula S, Oliveira RM, Aderaldo LC, Pontes MAA, Cruz R, de Gonçalves HS, Penna MLF, Penna GO, Stefani MMA.

Front Immunol. 2018 May 14;9:915. doi: 10.3389/fimmu.2018.00915. eCollection 2018.

6.

Development of a nanogold slot blot inhibition assay for the detection of antibodies against bovine herpesvirus type 1.

Japolla G, Cunha-Junior JP, Pajuaba ACAM, Taketomi EA, Bührer-Sékula S, Bataus LAM, de Souza GRL.

Arch Virol. 2018 Jun;163(6):1549-1557. doi: 10.1007/s00705-018-3763-4. Epub 2018 Feb 21.

PMID:
29468362
7.

Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae.

Benjak A, Avanzi C, Singh P, Loiseau C, Girma S, Busso P, Fontes ANB, Miyamoto Y, Namisato M, Bobosha K, Salgado CG, da Silva MB, Bouth RC, Frade MAC, Filho FB, Barreto JG, Nery JAC, Bührer-Sékula S, Lupien A, Al-Samie AR, Al-Qubati Y, Alkubati AS, Bretzel G, Vera-Cabrera L, Sakho F, Johnson CR, Kodio M, Fomba A, Sow SO, Gado M, Konaté O, Stefani MMA, Penna GO, Suffys PN, Sarno EN, Moraes MO, Rosa PS, Baptista IMFD, Spencer JS, Aseffa A, Matsuoka M, Kai M, Cole ST.

Nat Commun. 2018 Jan 24;9(1):352. doi: 10.1038/s41467-017-02576-z.

8.

Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.

Cruz RCDS, Bührer-Sékula S, Penna MLF, Penna GO, Talhari S.

An Bras Dermatol. 2017 Nov-Dec;92(6):761-773. doi: 10.1590/abd1806-4841.20176724. Review.

9.

Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.

Penna GO, Bührer-Sékula S, Kerr LRS, Stefani MMA, Rodrigues LC, de Araújo MG, Ramos AMC, de Andrade ARC, Costa MB, Rosa PS, Gonçalves HS, Cruz R, Barreto ML, Pontes MAA, Penna MLF.

PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005725. doi: 10.1371/journal.pntd.0005725. eCollection 2017 Jul.

10.

Whole genome sequencing distinguishes between relapse and reinfection in recurrent leprosy cases.

Stefani MMA, Avanzi C, Bührer-Sékula S, Benjak A, Loiseau C, Singh P, Pontes MAA, Gonçalves HS, Hungria EM, Busso P, Piton J, Silveira MIS, Cruz R, Schetinni A, Costa MB, Virmond MCL, Diorio SM, Dias-Baptista IMF, Rosa PS, Matsuoka M, Penna MLF, Cole ST, Penna GO.

PLoS Negl Trop Dis. 2017 Jun 15;11(6):e0005598. doi: 10.1371/journal.pntd.0005598. eCollection 2017 Jun.

11.

[Factors associated with TB/HIV coinfection: evidence from notification data in the State of Amazonas, Brazil, 2001-2012].

Magno EDS, Saraceni V, Souza AB, Magno RDS, Saraiva MDGG, Bührer-Sékula S.

Cad Saude Publica. 2017 Jun 12;33(5):e00019315. doi: 10.1590/0102-311X00019315. Portuguese.

12.

Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR).

Hungria EM, Bührer-Sékula S, de Oliveira RM, Aderaldo LC, Pontes AA, Cruz R, Gonçalves HS, Penna ML, Penna GO, Stefani MM.

PLoS Negl Trop Dis. 2017 Feb 21;11(2):e0005396. doi: 10.1371/journal.pntd.0005396. eCollection 2017 Feb.

13.

Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil.

Hungria EM, Oliveira RM, Penna GO, Aderaldo LC, Pontes MA, Cruz R, Gonçalves HS, Penna ML, Kerr LR, Stefani MM, Bührer-Sékula S.

Infect Dis Poverty. 2016 Dec 6;5(1):110.

14.

Could Mycobacterium leprae Infection Be an Occupational Disease? A Survey in Healthcare Workers From an Endemic Area in the Amazonian Region.

Pacheco SE, Bührer-Sékula S, de Moura RS, Stefani MM, Oliveira ML, Saraceni V, Cordeiro-Santos M.

Infect Control Hosp Epidemiol. 2015 Dec;36(12):1464-6. doi: 10.1017/ice.2015.224. Epub 2015 Oct 12.

PMID:
26456726
15.

Temporal distribution of tuberculosis in the State of Amazonas, Brazil.

Garrido Mda S, Bührer-Sékula S, Souza AB, Ramasawmy R, Quincó Pde L, Monte RL, Santos LO, Perez-Porcuna TM, Martinez-Espínosa FE, Saraceni V, Cordeiro-Santos M.

Rev Soc Bras Med Trop. 2015;48 Suppl 1:63-9. doi: 10.1590/0037-8682-0055-2014. Epub 2015 Mar 1. Review.

16.

Description of leprosy classification at baseline among patients enrolled at the uniform multidrug therapy clinical trial for leprosy patients in Brazil.

Moura RS, Penna GO, Cardoso LP, de Andrade Pontes MA, Cruz R, de Sá Gonçalves H, Fernandes Penna ML, de Araújo Stefani MM, Bührer-Sékula S.

Am J Trop Med Hyg. 2015 Jun;92(6):1280-4. doi: 10.4269/ajtmh.14-0049. Epub 2015 May 4.

17.

Multidrug-resistant tuberculosis in the Amazonas State, Brazil, 2000-2011.

Garrido Mda S, Bührer-Sékula S, Souza AB, de Oliveira GP, Antunes IA, Mendes JM, Saraceni V, Martinez-Espinosa FE, Ramasawmy R.

Int J Tuberc Lung Dis. 2015 May;19(5):531-6. doi: 10.5588/ijtld.14.0291.

PMID:
25868020
18.

Patient profile and treatment satisfaction of Brazilian leprosy patients in a clinical trial of uniform six-month multidrug therapy (U-MDT/CT-BR).

Ferreira IP, Buhrer-Sékula S, De Oliveira MR, Gonçalves Hde S, Pontes MA, Penna ML, Cruz R, Penna GO.

Lepr Rev. 2014 Dec;85(4):267-74.

PMID:
25675651
19.

Results from the clinical trial of uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): decrease in bacteriological index.

Penna ML, Bűhrer-Sékula S, Pontes MA, Cruz R, Gonçalves Hde S, Penna GO.

Lepr Rev. 2014 Dec;85(4):262-6.

PMID:
25675650
20.

Phage display and synthetic peptides as promising biotechnological tools for the serological diagnosis of leprosy.

Alban SM, de Moura JF, Thomaz-Soccol V, Bührer Sékula S, Alvarenga LM, Mira MT, Olortegui CC, Minozzo JC.

PLoS One. 2014 Aug 29;9(8):e106222. doi: 10.1371/journal.pone.0106222. eCollection 2014.

21.

Tuberculosis infection control: potential benefit of a new rapid tuberculosis test in a human immunodeficiency virus/AIDS reference hospital.

Cordeiro-Santos M, Trajman A, Cobelens F, Durovni B, Gonçalves M, Bührer-Sékula S, Saraceni V.

Infect Control Hosp Epidemiol. 2014 Sep;35(9):1206-7. doi: 10.1086/677643. No abstract available.

PMID:
25111939
22.

Evaluation of a rapid serological test for leprosy classification using human serum albumin as the antigen carrier.

Moura RS, Penna GO, Fujiwara T, Pontes MA, Cruz R, Gonçalves Hde S, Penna ML, Cardoso LP, Stefani MM, Bührer-Sékula S.

J Immunol Methods. 2014 Oct;412:35-41. doi: 10.1016/j.jim.2014.06.014. Epub 2014 Jun 29.

PMID:
24983877
23.

Primary drug resistance among pulmonary treatment-naïve tuberculosis patients in Amazonas State, Brazil.

da Silva Garrido M, Ramasawmy R, Perez-Porcuna TM, Zaranza E, Chrusciak Talhari A, Martinez-Espinosa FE, Bührer-Sékula S.

Int J Tuberc Lung Dis. 2014 May;18(5):559-63. doi: 10.5588/ijtld.13.0191.

PMID:
24903793
24.

Mycobacterium tuberculosis infection in young children: analyzing the performance of the diagnostic tests.

Pérez-Porcuna TM, Ascaso C, Malheiro A, Abellana R, Martins M, Sardinha JF, Quincó P, Antunes IA, da Silva Garrido M, Bührer-Sékula S, Martinez-Espinosa FE.

PLoS One. 2014 May 30;9(5):e97992. doi: 10.1371/journal.pone.0097992. eCollection 2014.

25.

Phenolic glycolipid-I does not cross-react with visceral leishmaniasis sera in a Brazilian subset.

Scaliante Moura R, Bührer-Sékula S, Jerônimo SM, Martins Araújo Stefani M.

Clin Infect Dis. 2014 Jul 15;59(2):317-9. doi: 10.1093/cid/ciu277. Epub 2014 Apr 23. No abstract available.

PMID:
24759833
26.

Serology with ML Flow test in health professionals from three different states of Brazil.

Calado KL, Magnanini MM, Moura RS, Gallo ME, Bührer-Sékula S, Oliveira ML.

An Bras Dermatol. 2013 Nov-Dec;88(6):918-23. doi: 10.1590/abd1806-4841.20132139.

27.

Increased sensitivity in diagnosis of tuberculosis in HIV-positive patients through the small-membrane-filter method of microscopy.

Quincó P, Bührer-Sékula S, Brandão W, Monte R, Souza SL, Saraceni V, Palaci M, Dietze R, Cordeiro-Santos M.

J Clin Microbiol. 2013 Sep;51(9):2921-5. doi: 10.1128/JCM.00683-13. Epub 2013 Jun 26.

28.

Historical analysis of the records of sylvan yellow fever in the State of Amazonas, Brazil, from 1996 to 2009.

Saraiva Md, Amorim RD, Moura MA, Santos EC, Sampaio LS, Barbosa Md, Bührer-Sékula S.

Rev Soc Bras Med Trop. 2013 Mar-Apr;46(2):223-6. doi: 10.1590/0037-8682-1573-2013.

29.

Primary results of clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): reactions frequency in multibacillary patients.

Penna ML, Buhrer-Sékula S, Pontes MA, Cruz R, Gonçalves Hde S, Penna GO.

Lepr Rev. 2012 Sep;83(3):308-19.

PMID:
23356032
30.

Comparison of two rapid tests for anti-phenolic glycolipid-I serology in Brazil and Nepal.

Stefani MM, Grassi AB, Sampaio LH, Sousa AL, Costa MB, Scheelbeek P, Neupane KD, Hagge DA, Macdonald M, Cho SN, Oskam L, Bührer-Sékula S.

Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:124-31.

31.

Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil.

Hungria EM, Oliveira RM, Souza AL, Costa MB, Souza VN, Silva EA, Moreno FR, Nogueira ME, Costa MR, Silva SM, Bührer-Sékula S, Reed SG, Duthie MS, Stefani MM.

Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:104-11.

32.

Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.

Gonçalves Hde S, Pontes MA, Bührer-Sékula S, Cruz R, Almeida PC, Moraes ME, Penna GO.

Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:74-8.

33.

A clinical trial for uniform multidrug therapy for leprosy patients in Brazil: rationale and design.

Penna GO, Pontes MA, Cruz R, Gonçalves Hde S, Penna ML, Bührer-Sékula S.

Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:22-7.

34.

Primary multidrug-resistant tuberculosis and its control implications in the State of Amazonas, Brazil: report of 3 cases.

Garrido MS, Talhari AC, Antunes IA, Matsuda Jda S, Zaranza Ed, Martinez-Espinosa FE, Bührer-Sékula S.

Rev Soc Bras Med Trop. 2012 Jul-Aug;45(4):530-2.

35.

Impact of PGL-I seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study.

Düppre NC, Camacho LA, Sales AM, Illarramendi X, Nery JA, Sampaio EP, Sarno EN, Bührer-Sékula S.

PLoS Negl Trop Dis. 2012;6(6):e1711. doi: 10.1371/journal.pntd.0001711. Epub 2012 Jun 19.

36.

Factors associated with tuberculosis treatment default in an endemic area of the Brazilian Amazon: a case control-study.

Garrido Mda S, Penna ML, Perez-Porcuna TM, de Souza AB, Marreiro Lda S, Albuquerque BC, Martínez-Espinosa FE, Bührer-Sékula S.

PLoS One. 2012;7(6):e39134. doi: 10.1371/journal.pone.0039134. Epub 2012 Jun 12.

37.

Evaluation of new strategies for the diagnosis of tuberculosis among pediatric contacts of tuberculosis patients.

Pérez-Porcuna TM, Ascaso C, Ogusku MM, Abellana R, Malheiro A, Quinco P, Antunes I, Monte R, Tavares M, Garrido M, Bührer-Sékula S, Martinez-Espinosa FE.

Pediatr Infect Dis J. 2012 Sep;31(9):e141-6.

PMID:
22572746
38.

Nasal mucosa study of leprosy contacts with positive serology for the phenolic glycolipid 1 antigen.

Martins AC, Miranda A, Oliveira ML, Bührer-Sékula S, Martinez A.

Braz J Otorhinolaryngol. 2010 Sep-Oct;76(5):579-87. English, Portuguese.

39.

Correlation between ELISA and ML Flow assays applied to 60 Brazilian patients affected by leprosy.

Da Silva RC, Lyon S, Lyon AC, Grossi MA, Lyon SH, Bührer-Sékula S, Antunes CM.

Trans R Soc Trop Med Hyg. 2010 Aug;104(8):546-50. doi: 10.1016/j.trstmh.2010.05.001. Epub 2010 Jun 17.

PMID:
20621218
40.

The additional benefit of the ML Flow test to classify leprosy patients.

Bührer-Sékula S, Illarramendi X, Teles RB, Penna ML, Nery JA, Sales AM, Oskam L, Sampaio EP, Sarno EN.

Acta Trop. 2009 Aug;111(2):172-6. doi: 10.1016/j.actatropica.2009.04.009. Epub 2009 Apr 23.

PMID:
19393609
41.

A comparison of ML Flow serology and slit skin smears to assess the bacterial load in newly diagnosed leprosy patients in Brazil.

Lyon S, Lyon AC, Da Silva RC, Grossi MA, Lyon SH, Bührer-Sékula S, Rocha MO.

Lepr Rev. 2008 Jun;79(2):162-70.

PMID:
18711938
42.

The relation between seroprevalence of antibodies against phenolic glycolipid-I among school children and leprosy endemicity in Brazil.

Bührer-Sékula S, van Beers S, Oskam L, Lecco R, Madeira ES, Dutra MA, Luis MC, Faber WR, Klatser PR.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:81-8.

43.

Research regarding anti-PGL-I antibodies by ELISA in wild armadillos from Brazil.

Deps PD, Antunes JM, Faria C, Bührer-Sékula S, Camargo ZP, Opromola DV, Tomimori J.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:73-6.

44.

Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy.

Brito Mde F, Ximenes RA, Gallo ME, Bührer-Sékula S.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:67-72.

45.

Seroprevalence of ML Flow test in leprosy contacts from State of Minas Gerais, Brazil.

Andrade AR, Grossi MA, Bührer-Sékula S, Antunes CM.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:56-9.

46.

Evaluation of the agreement between clinical and laboratorial exams in the diagnosis of leprosy.

Teixeira AC, Cruvinel DL, Roma FR, Luppino LF, Resende LH, Sousa Td, Bührer-Sékula S, Goulart IM.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:48-55.

47.

Leprosy serology (ML Flow test) in borderline leprosy patients classified as paucibacillary by counting cutaneous lesions: an useful tool.

Barreto JA, Nogueira ME, Diorio SM, Bührer-Sékula S.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:45-7.

48.

Risk factors for ML Flow seropositivity in leprosy patients.

Grossi MA, Leboeuf MA, Andrade AR, Bührer-Sékula S, Antunes CM.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:39-44.

49.

The influence of ML Flow test in leprosy classification.

Grossi MA, Leboeuf MA, Andrade AR, Lyon S, Antunes CM, Bührer-Sékula S.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:34-8.

50.

The use of serology as an additional tool to support diagnosis of difficult multibacillary leprosy cases: lessons from clinical care.

Oliveira ML, Cavaliére FA, Maceira JM, Bührer-Sékula S.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:27-33.

Supplemental Content

Loading ...
Support Center